As the cost of drug development continues to rise and public markets shift their attention to companies with late-stage products, an increasing diversity of financing options are becoming available to biotech companies with early-stage clinical programs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms
Archives of Toxicology Open Access 23 January 2018
-
Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies
Journal of Open Innovation: Technology, Market, and Complexity Open Access 15 January 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kaitin, K.I. (ed.) Cost to develop new biotech products is estimated to average $1.2 billion. Tufts Center for the Study of Drug Development Impact Report, vol. 8 (Tufts Center for the Study of Drug Development, Boston, Massachusetts, November/December 2006)
Bouchie, A.J. Optioning your drugs. The Scientist 20, 76 (2006).
Schiff, L. & Murray, F. Biotechnology financing dilemmas and the role of special purpose entities. Nat. Biotechnol. 22, 271–277 (2004).
Ransom, J. A reprise for collaborative financing in biotech. Nat. Biotechnol. 24, 873–874 (2006).
<http://www.pharmadd.com/archives/July%202006/MM%20Deals%20Bring%20Value.asp>
Longman, R. No dilution necessary: the promise of project financing. In Vivo 23, 12 (2005).
Acknowledgements
The authors would like to thank Sam Hall of Symphony Capital LLC, who assisted in the preparation of this article.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kessel, M., Frank, F. A better prescription for drug-development financing. Nat Biotechnol 25, 859–866 (2007). https://doi.org/10.1038/nbt0807-859
Issue Date:
DOI: https://doi.org/10.1038/nbt0807-859
This article is cited by
-
Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro–in vivo extrapolation (IVIVE)
Archives of Toxicology (2019)
-
Innovative organotypic in vitro models for safety assessment: aligning with regulatory requirements and understanding models of the heart, skin, and liver as paradigms
Archives of Toxicology (2018)
-
Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies
Journal of Open Innovation: Technology, Market, and Complexity (2016)
-
Start-ups weigh benefits of corporate incubators
Nature Biotechnology (2008)